<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Palatino;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0in;
margin-right:0in;
margin-bottom:0in;
margin-left:.5in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
p.msonormal0, li.msonormal0, div.msonormal0
{mso-style-name:msonormal;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:11.0pt;
font-family:"Calibri",sans-serif;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri",sans-serif;
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1219977054;
mso-list-type:hybrid;
mso-list-template-ids:127450522 67698705 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l0:level1
{mso-level-text:"%1\)";
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level2
{mso-level-number-format:alpha-lower;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level3
{mso-level-number-format:roman-lower;
mso-level-tab-stop:none;
mso-level-number-position:right;
text-indent:-9.0pt;}
@list l0:level4
{mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level5
{mso-level-number-format:alpha-lower;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level6
{mso-level-number-format:roman-lower;
mso-level-tab-stop:none;
mso-level-number-position:right;
text-indent:-9.0pt;}
@list l0:level7
{mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level8
{mso-level-number-format:alpha-lower;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-.25in;}
@list l0:level9
{mso-level-number-format:roman-lower;
mso-level-tab-stop:none;
mso-level-number-position:right;
text-indent:-9.0pt;}
@list l1
{mso-list-id:1741251921;
mso-list-template-ids:1049662680;}
@list l2
{mso-list-id:1869830911;
mso-list-template-ids:-2008270308;}
@list l3
{mso-list-id:1939176138;
mso-list-template-ids:-180187940;}
@list l3:level1
{mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level2
{mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level3
{mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level4
{mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level5
{mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level6
{mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level7
{mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level8
{mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;}
@list l3:level9
{mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-305.html" target="_blank">Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence
obesity related behaviors (e.g., dietary intake, physical activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by
their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-related policy or program offers an uncommon and scientifically-compelling research opportunity
that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded
within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due September 22, 2021; October 14, 2021; November 9, 2021; December 9, 2021; January 10, 2022; February 10, 2022; March 10, 2022; April 11, 2022; May 10, 2022; June 9, 2022; July 11,
2022; August 9, 2022; September 9, 2022; October 7, 2022; November 9, 2022; December 9, 2022; January 10, 2023; February 9, 2023; March 9, 2023; April 11, 2023; May 9, 2023; June 9, 2023; July 11, 2023; August 9, 2023; September 8, 2023; October 10, 2023;
November 9, 2023; December 11, 2023; January 9, 2024; February 9, 2024; March 8, 2024; April 9, 2024; May 8, 2024; June 10, 2024, July 9, 2024; August 9, 2024; and September 10, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for September 22, 2021 due date: September 9.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="http://earlychildhoodfoundation.org/" target="_blank">Caplan Foundation for Early Childhood Grants</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The Caplan Foundation for Early Childhood is an incubator of promising research and development projects that appear likely to improve the welfare of young children, from infancy through
7 years, in the United States. Welfare is broadly defined to include physical and mental health, safety, nutrition, education, play, familial support, acculturation, societal integration and childcare. Grants are only made if a successful project outcome will
likely be of significant interest to other professionals, within the grantee’s field of endeavor, and would have a direct benefit and potential national application. The Foundation’s goal is to provide
<b>seed money</b> to implement those imaginative proposals that exhibit the greatest chance of improving the lives of young children,
<b>on a national scale</b>. Because of the Foundation’s limited funding capability, it seeks to maximize a grant’s potential impact.<o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo3"><span style="font-family:Palatino">Early Childhood Welfare: Children can only reach their full potential when all aspects of their development — intellectual, emotional and physical
— are supported. Providing a safe and nurturing environment for infants and preschoolers is essential, as is imparting to them the skills of living in a culturally diverse world. To that end, the foundation supports programs that research best child-rearing
practices and identify models that can provide creative, caring environments in which all can children thrive.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo3"><span style="font-family:Palatino">Early Childhood Education and Play: Research shows that children need to be stimulated as well as nurtured early in life if they are to succeed in
school, work, and life. That preparation relates to every aspect of a child’s development, and everywhere a child learns — at home, in childcare settings and in preschool. The foundation seeks to improve the quality of both early childhood teaching and learning
through the development of innovative curricula and research based pedagogical standards, as well as the design of imaginative play materials and learning environments.<o:p></o:p></span></li><li class="MsoListParagraph" style="margin-left:0in;mso-list:l0 level1 lfo3"><span style="font-family:Palatino">Parenting Education: To help parents create nurturing environments for their children, the foundation supports programs that teach parents about
developmental psychology, cultural child-rearing differences, pedagogy, issues of health, prenatal care, and diet, as well programs that provide both cognitive and emotional support to parents.<o:p></o:p></span></li></ol>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Letter of inquiry due September 30, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: September 20.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-291.html" target="_blank">R01: Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and
Coordination of Needed Mental Health Services for Children and Adolescents (Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and test the effectiveness and implementation of family navigator models designed
to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator
model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers
to optimize care, and through the use of technology – to monitor the trajectory of mental health symptoms and outcomes over time. Applicants are required to develop and test the navigator model’s ability to promote early access, engagement, coordination and
optimization of mental health treatment and services for children and adolescents as soon as symptoms are detected. Applicants are also required to identify and test components of navigator models that drive improvements in mental health care; detect and interrogate
tailoring variables that optimize the ‘personalized match’ between the unique mental health needs of youth to the appropriate level of intensity and frequency of mental health services; and utilize emerging novel technologies to track and monitor the trajectory
of clinical, functional and behavioral progress toward achieving intended services outcomes.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-284.html">R01: Effectiveness of Implementing Sustainable Evidence-Based Mental Health Practices in Low-Resource Settings to
Achieve Mental Health Equity for Traditionally Underserved Populations (Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) encourages studies that develop and test the effectiveness of strategies for implementation and sustainable delivery of evidence-based mental
health treatments and services to improve mental health outcomes for underserved populations in low-resourced settings in the United States. Studies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from
evidence-based practices (EBPs) and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating new information about factors causing/reducing disparities are strongly encouraged,
including due consideration of the needs of individuals across the life span.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22.<o:p></o:p></span></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-292.html" target="_blank">R34: Pilot Studies to Test the Initiation of a Mental Health Family Navigator Model to Promote Early
Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and pilot test the effectiveness and implementation of existing family navigator
models designed to promote early access, engagement, coordination and optimization of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines
a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment
and service providers to optimize care, and through the use of technology – to monitor the trajectory of mental health symptoms and outcomes over time. Applicants are required to develop and pilot test the navigator model’s ability to promote early access,
engagement, coordination and optimization of mental health treatment and services for children and adolescents as soon as symptoms are detected. Applicants are also required to identify and pilot test components of navigator models that drive improvements
in mental health care; detect and interrogate tailoring variables that optimize the ‘personalized match’ between the unique mental health needs of youth to the appropriate level of intensity and frequency of mental health services; and utilize emerging novel
technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes.
<b>Standard dates apply. Expires September 8, 2024. <span style="color:red">Med-RA deadline to receive draft documents for October 16, 2021 standard date: October 5.<o:p></o:p></span></b></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-283.html">R34: Implementing and Sustaining Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Equity
in Outcomes (Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) supports pilot work for subsequent studies testing the effectiveness of strategies to deliver evidence-based mental health services, treatment
interventions, and/or preventive interventions (EBPs) in low-resourced mental health specialty and non-specialty settings within the United States. The FOA targets settings where EBPs are not currently delivered or delivered with fidelity, such that there
are disparities in mental health and related functional outcomes (e.g., employment, educational attainment, stable housing, integration in the community, treatment of comorbid substance use disorders) for the population(s) served. Implementation strategies
should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from EBPs and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations. Research generating
new information about factors causing/reducing disparities is strongly encouraged, including due consideration for the needs of individuals across the life span.
<b>Standard dates apply. Expires September 8, 2024. <span style="color:red">Med-RA deadline to receive draft documents for October 16, 2021 standard date: October 5.<o:p></o:p></span></b></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:red"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-316.html" target="_blank">Innovative Mental Health Services Research Not Involving Clinical Trials (R01)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative research that will inform and support the delivery of high-quality, continuously improving mental
health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities that strengthen the public
health impact of NIMH-supported research as described in <a href="https://www.nimh.nih.gov/about/strategic-planning-reports/goal-4-strengthen-the-public-health-impact-of-nimh-supported-research">
Goal 4 of the NIMH Strategic Plan</a>.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Proposed research should seek to:<o:p></o:p></span></p>
<ol style="margin-top:0in" start="1" type="1">
<li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of
mental health services, which may serve as targets in future service delivery intervention development;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Integrate and analyze large data sets to understand factors affecting mental health services outcomes using advanced computational and predictive analytic
approaches;<o:p></o:p></span></li><li class="MsoNormal" style="mso-list:l3 level1 lfo6"><span style="font-size:12.0pt;font-family:Palatino">Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals.<o:p></o:p></span></li></ol>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Standard dates apply. Expires September 8, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 5, 2021 standard date: September 22.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Dementia Care and Caregiver Support (R61 / R33 and R01)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-308.html">R61 / R33: Pragmatic Trials for Dementia Care and Caregiver Support (Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement will support pragmatic trials within Stage IV of the
<a href="https://www.nia.nih.gov/research/dbsr/nih-stage-model-behavioral-intervention-development">
NIH Stage Model</a> to improve dementia care across multiple dementia care settings that will: (1) be designed to address practical comparative questions faced by Alzheimer’s disease (AD) and AD-related dementia (ADRD) patients, clinicians, and caregivers (both
paid and unpaid); (2) include broad and diverse populations; and (3) be conducted in real-world settings with adequate sample size. These trials are intended to produce results that can be directly adopted by healthcare providers, patients, or caregivers for
rapid dissemination and implementation. Successful applications will: (1) improve quality of care of persons with dementia; (2) improve quality of life for persons with dementia and their informal caregivers; (3) deliver more patient-focused, cost-effective
care across multiple settings; and/or (4) reduce disparities in dementia care.<o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-21-307.html">R01: Dementia Care and Caregiver Support Intervention Research (Clinical Trial Required)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the
<a href="https://www.nia.nih.gov/research/dbsr/nih-stage-model-behavioral-intervention-development">
NIH Stage Model</a> to address the care needs and promote the health, function, and well-being of persons with Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD) and of those providing their care. The NIH Stage Model offers a framework
to: (1) support development of efficacious interventions that are defined by their principles; and (2) ensure that these efficacious interventions can be administered in the community or in health systems with fidelity to the intervention’s principles. This
includes the development, testing, and validation of scalable training materials and procedures so that these interventions can be delivered with fidelity in community settings or health systems. Settings can include the home, community, or formal care settings,
such as nursing homes, assisted living facilities, nursing and rehabilitation centers, hospitals, adult day care, and specialized hospice settings. The overarching purpose of this FOA is to help to lay the groundwork for real-world implementation of AD/ADRD
care and caregiving interventions. The principle-based interventions under development may target behavioral, psychological, interpersonal, social, or institutional processes and may be designed for use at the individual, family, dyad, group, community, or
health-systems level. Applications may propose mechanism-focused intervention research for individuals living with dementia or for individuals or systems providing care for people at any stage of AD/ADRD. Applications proposing the development of interventions
that address the principles underlying the care needs and challenges for individuals from diverse racial, ethnic, and socioeconomic backgrounds are strongly encouraged. Applications that involve interdisciplinary expertise and translational expertise (e.g.,
basic behavioral, social, psychological, or neurobiological science expertise relevant to hypothesized intervention mechanisms; expertise in the AD/ADRD service delivery system; and clinical psychological science expertise in areas outside of aging or AD/ADRD,
but potentially relevant to AD/ADRD caregiver research, etc.) are also strongly encouraged. Applications may propose to create, modify, and test AD/ADRD care and caregiver support interventions based upon hypothesized mechanisms of action and are encouraged
to incorporate a test of essential components or mechanisms of change using an appropriate methodological approach.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 7, 2021; February 10, 2022; October 11, 2022; February 10, 2023; October 10, 2023; and February 13, 2024.
<span style="color:red">Med-RA deadline to receive draft documents for October 7, 2021 due date: September 27.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-001.html">Biomarkers for the Lewy Body Dementias (U01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven clinical research applications that are focused on discovering novel diagnostic, prognostic,
and/or therapeutic biomarkers for the Lewy Body Dementias (LBD). Biomarker research must be conducted in patients with LBD, must follow Parkinson’s Disease Biomarker Program (PDBP) protocols for clinical assessment and biospecimen collection, and must be broadly
shareable through the PDBP repositories.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 22, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 11.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-023.html">Multi-Disciplinary Collaborations to Understand Mechanisms of Systemic Immune Signaling and Inflammation in ADRD
and its Progression (R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">Recent findings have raised the hypothesis that systemic immune responses could play direct or indirect roles in brain neurodegeneration leading to AD/ADRD and have been significantly
less studied than immune responses confined exclusively to within the brain parenchyma. The purpose of this funding opportunity announcement (FOA) is to support partnerships and new collaborations between neuroscientists and immunologists to expand the research
base in this area with the long-term goal of bringing more immunology expertise into the AD/ADRD field and to support further work in this area through investigator-initiated and other mechanisms.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due October 22, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 11.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://www.fmmjua.com/fmmjua/pagelets/Grant_Award_Decision.pdf" target="_blank">Florida Medical Malpractice Joint Underwriting Association Grants for Partnerships in Improving
the Safety of Health Care Services: The Alvin E. Smith Safety of Health Care Services Grant Program</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this RFA is to support projects that are intended to (1) identify, develop, test, and implement safe practice initiatives in inpatient and/or outpatient settings; and (2)
share the findings and lessons learned including the challenges and barriers to developing and implementing these interventions through validated tools, products, and/or health care safety toolkits. The interventions and any resulting implementation toolkits
shall be made publicly available so that they may be adapted and/or adopted by other health care organizations.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 8, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 26.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-024.html" target="_blank">Clinical and Biological Measures of TBI-related dementia including Chronic Traumatic Encephalopathy
(R01 Clinical Trial Not Allowed)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This FOA invites investigation of biological and clinical measures of TBI-related progressive neurodegeneration and neurocognitive decline associated with increased risk for dementia and
/or traumatic encephalopathy syndrome (TES) (clinicopathologic diagnostic counterpart to the neuropathological diagnosis of Chronic Traumatic Encephalopathy). Investigations should be based on existing, well-characterized populations of patients with a history
of TBI that are enriched for increased risk of cognitive impairment or dementia and can continue to be followed longitudinally; additional subjects may be recruited as appropriate. The overall goal is to advance knowledge of the underlying pathophysiology
and clinical characterization of the chronic effects of TBI that distinguish static-chronic TBI cognitive impairment from those that lead to progressive neurodegeneration associated with TES and dementia. A critical feature of this FOA includes the broad sharing
of clinical, neuroimaging, physiological, and biospecimen data and to create a data and associated biofluid resource for the broader community to further advance research in this area.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 10, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: October 28.</span><o:p></o:p></span></b></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-022.html">Fentanyl and its Analogs: Effects and Consequences for Treatment of Addiction and Overdose (UG3 / UH3 Clinical
Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">The purpose of this UG3/UH3 Phased Innovation Award Funding Opportunity Announcement is to support research to understand and respond to the new challenges in treating drug addiction and
overdose, introduced by the presence of fentanyl and its analogs (fentanyls) in illicit drug supplies. Applications should focus on understanding and treating opioid and polydrug use disorders (including overdose), wherein fentanyls are a major contributor
and their presence has altered previous estimations of the scope, impact and treatment of the problem. The research may include preclinical, clinical, epidemiological or even post-mortem studies. Studies should have high significance in order to quickly yield
improvements in understanding and to provide effective responses to the problems caused by illicit fentanyls. Responsive studies might focus on how fentanyls are complicating treatment of opioid or poly-drug addiction / overdose and might establish underlying
mechanisms. Studies might also design / test novel or revised mechanism-based treatment strategies based on differences in pharmacological responses to fentanyls compared with semisynthetic opiates. Studies aimed at developing new or repurposed medications
or therapeutic devices should aim to significantly advance the program towards FDA approval. Responsive studies may also require the development and implementation of improved sampling and analytical techniques to qualitatively and quantitatively evaluate
clinical and postmortem toxicological samples. The aims of such analyses would include improving clinical treatment and understanding the public health consequences of fentanyls addiction and overdose.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due November 11, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: November 1.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><a href="https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-058.html">American Women: Assessing Risk Epidemiologically (AWARE) (R01 Clinical Trial Optional)</a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino">This Funding Opportunity Announcement (FOA) will support research that combines epidemiologic methods, digital technology, and data science approaches to better understand HIV prevention,
transmission, and early care-cascade points for women living in the US. Applications must: 1) determine the best ways to identify, enroll, and retain cohorts of women living in the United States (US) who are behaviorally vulnerable to HIV; and 2) develop a
knowledgebase comprised of cohort data from women augmented with other data sources including big data sources. Findings should not only lead to a better understanding of how women remain vulnerable to HIV but also inform future pilot interventions aimed at
decreasing the incidence of HIV and other sexually transmitted infections (STIs) among cisgender, transgender, and gender non-conforming women.<o:p></o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino">Due December 9, 2021.
<span style="color:red">Med-RA deadline to receive draft documents: November 29.</span></span></b><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-size:12.0pt;font-family:Palatino"><o:p> </o:p></span></p>
<p class="MsoNormal"><b><span style="font-size:12.0pt;font-family:Palatino;color:black">To search for additional funding opportunities, please visit </span></b><span style="font-size:12.0pt;font-family:Palatino;color:black"><a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=" title="https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV69"><b><span style="color:#954F72">CoM’s
unofficial funding opportunities blog</span></b></a><b>.</b></span><span style="font-size:12.0pt;font-family:Palatino"><o:p></o:p></span></p>
</div>
</body>
</html>